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Abstract Apoptosis, the most common form of cell
death, is a key mechanism in the build up and maintenance
of both innate and adaptive immunity. Central to the
apoptotic process is a family of intracellular cysteine pro-
teases with aspartate-specificity, called caspases. Caspases
are counter-regulated by multiple anti-apoptotic molecules,
and the expression of the latter in leukocytes is largely
dependent on survival factors. Therefore, the physiologic
rates of apoptosis change under pathologic conditions. For
instance, in inflammation, the expression of survival fac-
tors is usually elevated, resulting in increased cell survival
and consequently in the accumulation of the involved
immune cells. In many allergic diseases, eosinophil apop-
tosis is delayed contributing to both blood and tissue
eosinophilia. Besides eosinophils, apoptosis of other leu-
kocytes is also frequently prevented or delayed during
allergic inflammatory processes. In contrast to inflamma-
tory cells, accelerated cell death is often observed in
epithelial cells, a mechanism, which amplifies or at least
maintains allergic inflammation. In conclusion, deregulated
cell death is a common phenomenon of allergic diseases
that likely plays an important role in their pathogenesis.
Whether the apoptosis is too little or too much depends on
the cell type. In this review, we discuss the regulation of
the lifespan of the participating leukocytes in allergic
inflammatory responses.
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Introduction
Allergic diseases are the consequence of hyperreactivity
reactions of the immune systems towards exogeneous
antigens (allergens). Most allergic reactions are associated
with an increased T helper (Th) 2 activation, resulting in
elevated IgE levels and eosinophilia. Allergic diseases,
including asthma, rhinitis, conjunctivitiy, atopic eczema, as
well as food and drug allergies are major contributors to
morbidity in the civilized world, and sometimes even cause
mortality. With the expanding knowledge, the field of
allergy, along with the broader framework of immunology,
has dramatically changed concepts in recent years. How-
ever, in spite of the progress, the regulation of cell death in
allergic diseases is relatively little investigated and its
contribution to the pathogenesis of the different disorders
not well understood and reflected, respectively.
Similar to other types of inflammatory responses,
accumulation of subgroups of leukocytes occur during the
initiation and maintenance phases, whereas inflammatory
cell numbers decline in the resolution phase of allergic
inflammation. The changes in cell numbers during
inflammation are largely due to changes of rates of both
cell generation and cell death. Important leukocyte sub-
groups believed to play critical roles in the
pathophysiology of allergic inflammation involve dendritic
cells, T cells, mast cells, and eosinophils. The most com-
mon form of cell death of leukocytes is apoptosis.
That apoptosis is deregulated in allergic diseases is often
not reflected in reviews dealing with the pathophysiologic
relevance of apoptosis in diseases. However, since
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approximately one-third of the population within the
countries of the industrial world suffers from one or several
allergic diseases [1], it is important that apoptosis research
in these disorders is not neglected. Here, we review the
current knowledge on the regulation of cell death during
allergic inflammatory responses. Due to space limitations,
we will concentrate on summarizing important molecular
events that change apoptosis rates in allergic diseases and
will not cover basic knowledge on apoptosis pathways.
Cell death of mast cells
Mast cells are resident in all normal tissues, where they are
believed to play an important role in tissue homeostasis,
wound healing, and host defense. Mast cell activation is a
characteristic feature of allergic responses, leading to the
release of a large number of important mediators that can
cause chronic inflammation. Mast cells are also involved in
the mechanisms leading to bronchial hyperreactivity [2].
Therefore, how mast cell homeostasis is regulated may
have significant effects on normal physiology and con-
tributes to the genesis of allergic inflammatory diseases.
Mast cell numbers are increased in allergic inflamma-
tory responses [3], and preventing apoptosis might
contribute to this phenomenon. Stem cell factor (SCF),
interleukin (IL)-3, IL-4, IL-5, IL-6, and nerve growth
factor (NGF) have been described to promote mast cell
survival [4–6]. On the other hand, it has been reported that
exposure of murine bone-marrow-derived mast cells to
IL-3, IL-4, and IL-10 downregulate the SCF receptor kit as
well as the high-affinity IgE receptor, resulting in mast cell
apoptosis [7].
SCF is considered as being the most crucial survival
factor for mast cells. The crucial role of SCF for regulating
mast cell numbers is best reflected by experimental in vivo
models. Mice with deficient expression of SCF or kit have
almost complete lack of mast cells in their tissues [8, 9].
SCF is secreted from several cell types, such as stromal
cells, fibroblasts, endothelial cells, and mast cells them-
selves [10, 11]. Injection of SCF to the skin increases mast
cell numbers. Moreover, a gain of functional mutations of
kit causes systemic mastocytosis [12].
Following binding of SCF to kit, kit is dimerized and
autophosphorylated on tyrosine residues. This initiates
multiple intracellular signaling pathways, which involve
phosphatidylinositol-3-kinase (PI3K), mitogen activated
protein kinase (MAPK), phospholipase C c (PLCc), Src
kinase, and Janus kinase/Signal transducers and activators
of transcription (Jak/STAT), resulting in gene activation
[13]. It was found that Bim is both inactivated and reduced
due to SCF stimulation of mast cells [14]. Interestingly,
cross-linking of the high-affinity IgE receptor also leads
to apoptosis inhibition, which is mediated by increased
Bcl-xL and A1 expression [15, 16]. Increased survival
following mast cell activation may also be the consequence
of the release of survival factors, which then act in an
autocrine manner [17, 18].
Besides the anti-apoptotic mechanisms, mast cells
additionally carry functional death receptors. For instance,
mast cell apoptosis can be induced following ligation of
Fas and TNF-related apoptosis inducing ligand (TRAIL)
receptors [19, 20]. Interestingly, immunoglobulin E (IgE)-
mediated activation of mast cells increased their sensitivity
to undergo TRAIL-induced apoptosis, although the mech-
anism(s) responsible for these functional effects remain to
be investigated [20, 21]. In the resolution phase of allergic
inflammation, in which survival cytokine expression is
likely decreased, the induction of mast cell apoptosis crit-
ically involves the BH3-only protein Puma [22].
Cell death of eosinophils, neutrophils, and basophils
Eosinophils are prominent effector cells in many allergic
and parasitic inflammatory responses [23]. They are con-
stantly generated in the bone-marrow and short-lived [24].
Moreover, eosinophils are relatively rare and their contri-
bution to blood leukocyte numbers does not exceed 4%
under physiologic conditions. IL-5 represents a crucial
cytokine for eosinophil differentiation, activation, and
survival [25]. Therefore, in diseases with elevated levels of
IL-5, increased numbers of eosinophils are observed [26].
The importance of IL-5 for delayed eosinophil apoptosis in
tissues has been directly demonstrated in nasal polyp
explants [27]. Delayed eosinophil apoptosis has also been
demontrated in experimental in vivo models of allergic
disease [28]. Moreover, there was an inverse correlation
between numbers of apoptotic eosinophils in sputum from
asthmatic patients and levels of IL-5 and eotaxin, again
indicating that IL-5 (and perhaps eotaxin) acts as an
eosinophil survival factor in vivo [29]. Besides IL-5, other
eosinophil survival cytokines are IL-3 and granulocyte/
macrophage colony-stimulating factor (GM-CSF). Inter-
estingly, eotaxin-1 [30], leptin [31], and CD40 ligand [32]
are also able to prolong eosinophil survival in vitro.
The molecular mechanisms involved in cytokine-medi-
ated enhanced eosinophil survival include increased
expression of Bcl-xL [33], delayed Bid cleavage [34],
inhibition of Bax translocation to mitochondria [35], and
delayed Bax cleavage [31], resulting in delayed mito-
chondrial cytochrome c and second mitochondria-derived
activator of caspase (Smac) release and caspase activation
[31, 35]. IL-5 has also been shown to induce cIAP2 and
survivin, suggesting that delay of apoptosis can also be
achieved by blocking caspases [36]. The signal
440 Apoptosis (2009) 14:439–446
123
transduction mechanisms leading to gene expression of
anti-apoptotic proteins involve tyrosine kinases [37, 38],
MAPK [37], PI3K [39], Jak/STAT [40, 41], and NF-jB
pathways [42]. In contrast, the c-Jun N-terminal kinase
(JNK) pathway seems to mediate constitutive eosinophil
apoptosis [43].
Eosinophils also carry functional death receptors. For
instance, eosinophils express Fas receptors that initiate
apoptosis upon activation, even in the presence of survival
cytokines [44]. In contrast, nitric oxide, that is increasingly
generated during allergic inflammatory responses, coun-
terregulates Fas receptor-induced apoptosis [45]. TRAIL
and TNF receptors are also expressed on eosinophils, and
were reported to mediate eosinophil survival [46, 47]. In
contrast, recombinant surfactant protein-D (SP-D) has been
shown to induce apoptosis in eosinophils from allergic
patients, but not from healthy donors, although the mech-
anism remains unclear [48]. Eosinophil apoptosis can also
be induced as a consequence of sialic acid binding
immunoglobulin-like lectin (Siglec)-8 ligation [49].
Moreover, IL-5 increases Siglec-8 mediated death in a
partially caspase-independent manner (Fig. 1) [50].
Therefore, the eosinophil cell death under these condition
is unlikely apoptosis, but may represent an autophagic-like
cell death [51]. Recently, a natural ligand for Siglec-8 has
been identified [52]. Interestingly, Siglec-8 can also be
ligated by physiologic anti-Siglec-8 autoantibodies [53].
Moreover, ligation of mouse Siglec-F, the closest func-
tional paralog of human Siglec-8, selectively reduces blood
and tissue eosinophils in experimental mouse models [54].
Glucocorticoids that are often used as anti-inflammatory
drugs in allergic inflammatory responses directly induce
eosinophil apoptosis, although the molecular mechanism of
this drug’s action on cell survival remains unclear [55].
Nevertheless, this effect might be important since asth-
matic patients exhibit an increased proportion of apoptotic
eosinophils in their airway secretions following clinical
improvement with successful glucocorticoid therapy [56].
Theophylline has also been reported to induce eosinophil
apoptosis [57], but the clinical significance of this finding is
unclear. Agents that increase intracellular cAMP may also
modify eosinophil apoptosis, depending on the inflamma-
tory cytokine environment [58].
Although neutrophils can be present in bronchial asthma
[59], they are usually not dominant in chronic allergic
inflammatory responses. However, it is interesting to
compare the regulation of apoptosis between eosinophils
and neutrophils, since both cell types are granulocytes.
Neutrophils and eosinophils express surface molecules,
which initiate either survival or death signals. Both cell
types respond with enhanced survival when stimulated with
GM-CSF, and with enhanced apoptosis following ligation
of Fas receptors. Like in eosinophils, Fas stimulation
results in neutrophil apoptosis even in the presence of
survival factors [60]. On the other hand, there are also
surface receptors, which are expressed on either eosino-
phils or neutrophils. For instance, IL-5 is a specific survival
factor for eosinophils, whereas G-CSF specifically pro-
longs the lifespan of neutrophils. In addition, the
complement factor C5a enhances neutrophil [61], but not
eosinophil survival (unpublished observation). Siglec-8
transduces death signals in eosinophils, but not neutrophils.
In contrast, Siglec-9 is a death receptor on neutrophils that
is not expressed on eosinophils [62]. Moreover, the nico-
tinic acid receptor GPR109A was recently identified on the
surface of neutrophils, but not eosinophils [63]. There seem
to be also differences regarding the mechanism of cell
death regulation in association with DNA release between
neutrophils and eosinophils [64, 65]. Interestingly,
hypoxia, which induces apoptosis in most cell types, delays
apoptosis in neutrophils [66]. The effect of hypoxia on
eosinophil apoptosis is unknown.
Apoptosis in eosinophils and neutrophils is also regu-
lated by drugs and/or compounds. Glucocorticoids, which
induce eosinophil apoptosis (see above), delay the neu-
trophil apoptotic program [55]. On the other hand, nitric
oxide donors promote neutrophil apoptosis, but somehow
block eosinophil apoptosis [45]. Furthermore, the effect of
phenylarsine oxide on apoptosis is different in neutrophils
and eosinophils at a given concentration [67]. These data
suggest that differences exist in the expression of intra-
cellular components of cell death pathways between
eosinophils and neutrophils. Indeed, caspases, although
present, are somehow more difficult to activate in eosino-
phils compared with neutrophils [68]. In contrast, the
expression of Bcl-2 family members seems to be similar in
Siglec-8
IL-5
Caspase-independent 
cell death
Fas
ROS Caspases ROS Caspases
Apoptosis
IL-5
Fig. 1 Different forms of cell death in eosinophils following Fas and
Siglec-8 ligation in the presence of IL-5. Both Fas and Siglec-8
ligation induce caspase activation and ROS generation in the absence
of concurrent survival cytokine stimulation, leading to apoptosis. In
the presence of IL-5, however, death programs are different. In
contrast to Fas ligation, which blocks anti-apoptotic signaling, Siglec-
8 ligation does not prevent IL-5-mediated caspase inactivation.
Caspase inhibition is associated with a largely caspase-independent
cell death, which depends on ROS
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eosinophils and neutrophils. Interestingly, Bcl-2, although
present in immature precursors, is no longer present in both
granulocyte types upon full maturation [69]. This obser-
vation may, at least partially, explain the short lifespan of
these cells. Bim, a BH3-only protein, seems to play a major
role in the regulation of neutrophil apoptosis [70]. The
expression and function of Bim in eosinophils remains to
be investigated. Taken together, the regulation of apoptosis
in eosinophils and neutrophils is at least partially different,
providing the opportunity to selectively target one granu-
locyte type without affecting the other by pharmacological
means.
In contrast to eosinophils and neutrophils, little is known
about the regulation of apoptosis in basophils, which rep-
resent the least abundant granulocyte population. Basophils
are considered, besides mast cells and eosinophils, as key
effector cells in allergic inflammation. Proinflammatory
and immunomodulatory activities of basophils include
secretion of histamine and the lipid mediator leukotriene
C4 as well as rapid production of IL-4 and IL-13, Th2-type
cytokines crucial for the development of allergy. The
regulation of basophil apoptosis is likely to be important
for the length and strength of allergic inflammation, since
negative regulators on basophil activity have not been
identified. IL-3 appears to be the only ligand that protects
basophil apoptosis with high efficacy [71]. In contrast,
ligation of Fas results in basophil apoptosis [72]. A recent
study demonstrated that IL-3 mediates its anti-apoptotic
effect on basophils through a Pim1-dependent signaling
pathway [73].
Cell death of T cells
T cells, in particular T cells producing Th2 cytokines, play
an important role in allergic inflammatory responses. For
instance, IL-4 and IL-13 enhance IgE production, IL-4,
IL-9, and IL-10 enhance mast cell growth; and IL-5 pro-
motes eosinophil accumulation [74]. This Th2 response is
the result of clonal expansion of allergen-specific T cells
and involves both increased proliferation and inhibition of
apoptosis. Although some observations in allergic inflam-
matory responses suggest prolonged survival of Th2 cells
[75], most of our information on the role of T cell apoptosis
in immune responses comes from experimental models.
Bcl-2 expression is required for the survival of mature,
resting T cells [76]. IL-4, IL-6, or IL-7 are required to
maintain Bcl-2 and Bcl-xL levels in these cells [77, 78].
Interaction of the T cell receptor (TCR) with major histo-
compatibility complex (MHC) class II molecules is
required to keep memory T cells alive [79].
The antigen-mediated stimulation of T cells results in a
change in requirements for survival. Activated T cells
produce IL-2 and are dependent on IL-2, and related
cytokines, for their survival [77, 78, 80]. IL-2 and related
cytokines maintain Bcl-2 and Bcl-xL levels [77, 78], and
IL-2 withdrawal requires activation of Bim to induce death
[81]. Repeated TCR activation sensitizes T cells to apop-
tosis, a process known as activation-induced cell death.
Upon activation, Th1 cells are initially resistant to Fas
ligand-induced death, but they gain sensitivity after several
days [82]. This increased susceptibility towards Fas
receptor-mediated apoptosis has been attributed to lower
levels of FLICE-like inhibitory protein (FLIP) and is IL-2-
dependent [83]. In Th2 cells, however, FLIP levels may not
decrease, resulting in Fas resistance [84]. Therefore, Th2
predominance in allergic diseases may largely be due to
increased Th1 cell apoptosis [85, 86].
In the resolution phase of inflammatory responses, most
activated T cells are killed. T cell apoptosis may occur by
two mechanisms: (1) by repeated stimulation of the TCR
with antigen in conjunction with MHC class II molecules,
and (2) by reduction in cytokine levels due to decreased
inflammation. The first mechanism requires Fas in Th1
cells, and Fas-deficient patients develop a lymphoprolif-
erative disease [87, 88]. In Th2 cells, which are Fas
resistant [84], granzyme B is critical for activation-induced
cell death (Fig. 2) [89]. This second mechanism requires
Bim [81] and can be blocked by high levels of Bcl-2 [90].
Th2 cell apoptosis in allergic diseases may also be
achieved by drug treatment. For instance, calcineurin
TCR
Fas-mediated
apoptosis
IL-2
FLIP
TCR
Lysosomes
Granzyme B
Caspase-independent 
cell death
Fig. 2 Distinct T cell receptor (TCR)-mediated death pathways in
Th1 and Th2 cells. Whereas Th1 cells gain Fas sensitivity due to
IL-2-dependent downregulation of FLIP during an immune response,
Th2 cells stay Fas resistant following TCR activation. In Th2 cells,
granzyme B is released from lysosomes mediating a caspase-
independent cell death
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inhibitors have been described to induce T cell apoptosis in
atopic eczema [91].
Almost nothing is known about the regulation of apop-
tosis of regulatory T cells. It is tempting to speculate,
however, that dysregulated apoptosis in these cells con-
tributes to the pathogenesis of allergic inflammatory
responses. Interestingly, it has been suggested that T reg-
ulatory cells induce effector CD4? T cell apoptosis in an
experimental model of inflammatory bowel disease [92].
Therefore, it is possible that regulatory T cells also fulfill
their function, at least partially, by mediating effector T
cell apoptosis in allergic diseases. Clearly, such a potential
mechanism deserves further investigation.
Cell death of dendritic cells
The role of dendritic cells in driving Th2 allergic responses
has received considerable attention in recent years. Den-
dritic cells have direct contact to incoming antigens. In the
presence of a danger signal, dendritic cells mature to pro-
fessional antigen-presenting cells, and interact with naive T
cells in draining lymph nodes. Dendritic cells can influence
polarization of T cells by the release of cytokines [93] and
their expression of costimulatory molecules [94] that are
both influenced by the local environment [95]. Dendritic
cells have been shown to be essential in the pathogenesis of
allergic diseases [96, 97].
The lifespan of mature dendritic cells is thought to be
approximately three days [98]. This short time may limit
the availability of antigen for T cells, and apoptosis
induction in dendritic cells may serve to regulate immune
responses. The lifespan of dendritic cells is determined by
both antigen-mediated and T cell signals. For instance,
ligands for Toll-like receptors (TLRs), CD40 ligand, or
tumor necrosis factor-related activation-induced cytokine
(TRANCE) promote dendritic cell survival via NF-jB
pathways [99–101]. One of the NF-jB target genes is Bcl-
xL, which is induced by both TLR ligands and T cell
signals. In addition, TLR ligands, but not T cell signals,
reduce Bcl-2 and induce Bim, thus limiting the lifespan of
dendritic cells [102]. One might, therefore, speculate that
immature dendritic cells receive first TLR ligands, which
are likely to set the lifespan of dendritic cells, before they
even enter the lymph node. A function of T cells might
then be to prolong the survival of dendritic cells, possibly
leading to a temporary and local enrichment of dendritic
cells.
It is has been demonstrated that increasing the lifespan
of mature dendritic cells is an important factor to
strengthen the inflammatory response under in vivo con-
ditions [102]. Therefore, it is likely that increased dendritic
cell survival also plays a role in allergic inflammatory
responses. Indeed, it has recently been reported that
apoptosis-resistant dendritic cells promote Th2 responses,
including IgE production in an experimental mouse model
[103]. Therapeutic approaches promoting dendritic cell
apoptosis appear to be promising [104], further pointing to
the possibility that the lifespan of dendritic cells is a critical
element in the generation and/or maintenance of allergic
diseases.
Cell death of epithelial cells
Epithelial cell apoptosis is a common phenomenon of
allergic inflammation. For instance, bronchial epithelial
apoptosis leads to epithelial shedding in asthma. Apoptosis
is mediated by activated T cell and eosinophils [105].
Another example of epithelial cell apoptosis in association
with allergy is seen in atopic eczema. Apoptosis of kerat-
inocytes has been reported to be a major cause of
spongiosis, which represents one of the hallmarks of atopic
eczema [106]. IFN-c, even at very low concentrations,
increases Fas expression on keratinocytes and renders these
cells susceptible to apoptosis [106]. Taken together, aller-
gic diseases are often associated with epithelial cell
damage, which likely amplifies or at least maintains the
inflammatory process.
Conclusion
A look at the molecular basis of many allergic diseases
reveals a cell death component that either accounts for the
disease or contributes to disease progression. Therefore,
current and future anti-allergic therapies should also be
analyzed in respect to their effects on cell death pathways.
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